12. Malignt pleuralt mesoteliom (C45)

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., ... Zalcman, G. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, 397(10272), 375-386.

Bissett, D., Macbeth, F. R., & Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clinical Oncology (Royal College of Radiologists), 3(6), 315-7.

Brcic, L., & Kern, I. (2020). Clinical significance of histologic subtyping of malignant pleural mesothelioma. Translational lung cancer research, 9(3), 924-933.

Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. (2017). TNM Classification of Malignant Tumours. Wiley.

Brustugun, O. T., Nilssen, Y., & Eide, I. J. Z. (2021). Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. Acta Oncologica, 60(10), 1250-1256.

Bydder, S., Phillips, M., Joseph, D. J., Cameron, F., Spry, N. A., DeMelker, Y., & Musk, A. W. (2004). A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. British Journal of Cancer, 91(1), 9-10.

Cao, C. Q., Yan, T. D., Bannon, P. G., & McCaughan, B. C. (2010). A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic Oncology, 5(10), 1692-703.

de Perrot, M., Feld, R., Cho, B. C., Bezjak, A., Anraku, M., Burkes, R., Roberts, H., Tsao, M. S., ... Johnston, M. R. (2009). Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27(9), 1413-8.

De Ruysscher, D., & Slotman, B. (2003). Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiotherapy and Oncology, 68(3), 299-302.

Ellis, P., Davies, A. M., Evans, W. K., Haynes, A. E., Lloyd, N. S., & Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2006). The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. Journal of Thoracic Oncology, 1(6), 591-601.

Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., ... CONFIRM trial investigators (2021). Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet. Oncology, 22(11), 1530-1540.

Grosso, F., Cerbone, L., & Curioni-Fontecedro, A. (2024). MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma. The Lancet. Respiratory medicine, 12(6), 423-424.

Hallifax, R. J., Talwar, A., Wrightson, J. M., Edey, A., & Gleeson, F. V. (2017). State-of-the-art: Radiological investigation of pleural disease. Respiratory Medicine, 124, 88-99.

Hassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., Gadiraju, M., Panou, V., ... Churpek, J. E. (2019). Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 116(18), 9008-9013.

Helland, Å., Solberg, S., & Brustugun, O. T. (2012). Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. Journal of Thoracic Oncology, 7(12), 1858-61.

Hollevoet, K., Reitsma, J. B., Creaney, J., Grigoriu, B. D., Robinson, B. W., Scherpereel, A., Cristaudo, A., Pass, H. I., ... van Meerbeeck, J. P. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. Journal of Clinical Oncology, 30(13), 1541-9.

Holsti, L. R., Pyrhonen, S., Kajanti, M., Mantyla, M., Mattson, K., Maasilta, P., & Kivisaari, L. (1997). Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncologica, 36(4), 397-405.

Kantor, T., & Wakeam, E. (2021). Landmark Trials in the Surgical Management of Mesothelioma. Annals of Surgical Oncology,

Kelly, R. J., Sharon, E., & Hassan, R. (2011). Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 73(3), 256-63.

Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., Flores, R., Friedberg, J. S., ... Vogelzang, N. J. (2009). Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27(18), 3007-13.

Lim, E., Waller, D., Lau, K., Steele, J., Pope, A., Ali, C., Bilancia, R., Keni, M., ... Investigators, M. 2. (2024). Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. The Lancet. Respiratory medicine, 12(6), 457-466.

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., Lee, Y. C. G., Dick, I. M., ... Røe, O. D. (2022). BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. Journal of Thoracic Oncology, 17(7), 921-930.

Marinaccio, A., Binazzi, A., Cauzillo, G., Cavone, D., Zotti, R. D., Ferrante, P., Gennaro, V., Gorini, G., ... Tumino, R. (2007). Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. European Journal of Cancer, 43(18), 2722-8.

Noonan, C. W. (2017). Environmental asbestos exposure and risk of mesothelioma. Annals of translational medicine, 5(11), 234.

O'Brien, M. E., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., Ashley, S., Rowell, N., & Sayer, R. (2006). A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Annals of Oncology, 17(2), 270-5.

O'Rourke, N., Garcia, J. C., Paul, J., Lawless, C., McMenemin, R., & Hill, J. (2007). A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiotherapy and Oncology, 84(1), 18-22.

Patel, A., Roshkovan, L., McNulty, S., Alley, E., Torigian, D. A., Nachiappan, A. C., Galperin-Aizenberg, M., Barbosa, E. M., ... Katz, S. I. (2021). Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study. Clinical Lung Cancer, 22(3), 210-217.e1.

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., ... Stahel, R. A. (2020). A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology, 31(12), 1734-1745.

Rusch, V. W., Chansky, K., Kindler, H. L., Nowak, A. K., Pass, H. I., Rice, D. C., Shemanski, L., Galateau-Sallé, F., ... IASLC Staging and Prognostic Factors Committee, ,. a. b. a. p. i. (2016). The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 11(12), 2112-2119.

Santoro, A., O'Brien, M. E., Stahel, R. A., Nackaerts, K., Baas, P., Karthaus, M., Eberhardt, W., Paz-Ares, L., ... Manegold, C. (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Journal of Thoracic Oncology, 3(7), 756-63.

Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., ... European Respiratory Society/European Society of Thoracic Surgeons Task Force (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal, 35(3), 479-95.

Shaw, P., & Agarwal, R. (2004). Pleurodesis for malignant pleural effusions. Cochrane Database of Systematic Reviews, (1)

Stahel, R. A., Weder, W., Lievens, Y., Felip, E., & ESMO Guidelines Working Group (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21 Suppl 5, v126-8.

Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., DeCamp, M. M., Swanson, S. J., ... Mentzer, S. J. (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. Journal of Thoracic and Cardiovascular Surgery, 117(1), 54-63.

Treasure, T., Lang-Lazdunski, L., Waller, D., Bliss, J. M., Tan, C., Entwisle, J., Snee, M., O'Brien, M., ... MARS trialists (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. The Lancet. Oncology, 12(8), 763-72.

van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., ... Giaccone, G. (2005). Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. Journal of Clinical Oncology, 23(28), 6881-9.

van Thiel, E. R., Surmont, V. F., & van Meerbeeck, J. P. (2011). Malignant pleural mesothelioma: when is radiation therapy indicated?. Expert Review of Anticancer Therapy, 11(4), 551-60.

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., ... Paoletti, P. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644.

Waite, K., & Gilligan, D. (2007). The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clinical Oncology (Royal College of Radiologists), 19(3), 182-7.

Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Betticher, D., ... Swiss Group for Clinical Cancer Research (2007). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Annals of Oncology, 18(7), 1196-202.

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., ... French Cooperative Thoracic Intergroup (IFCT) (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 387(10026), 1405-14.